New technique can closely control nanoparticle size and shape
A new technique has been demonstrated that will control the size and shape of nanoparticles which could lead to their use as a form of drug delivery.
List view / Grid view
A new technique has been demonstrated that will control the size and shape of nanoparticles which could lead to their use as a form of drug delivery.
US prosecutors have handed subpoenas to six pharmaceutical companies and distributors for their role in the opioid crisis, as reported.
The content sessions at CPhI Worldwide have revealed the coming trends that the pharmaceutical industry will see next year.
The global medical marijuana market will show impressive growth, a new report has said, but this could be hindered due to some doctors being reluctant to prescribe these products.
Remsima SC™ is the world’s first subcutaneous formulation of infliximab and has been approved in the EU for the treatment of people with rheumatoid arthritis.
The M&A between Novartis and The Medicines Company will add inclisiran, the potentially first-in-class treatment to reduce cholesterol, to the former’s pipeline.
Four companies are recalling batches of certain over-the-counter ranitidine medicines used to treat conditions such as stomach ulcers and heartburn.
According to a new report, the UK is leading the rest of Europe for early-stage clinical research into new medicines and vaccines, with more than 600 commercial clinical trials taking place in the NHS.
The Chinese National Medical Products Administration has given its approval to XTANDI® to treat prostate cancer, following a successful Phase III trial.
Based on results from two global randomised studies and a large open-label safety study, XCOPRI has been approved by the FDA as a treatment for partial-onset seizures in adults.
The investigational broadly neutralising antibody, N6LS, is to be developed by ViiV Healthcare for the treatment and prevention of HIV-1.
US Speaker Pelosi’s new drug pricing plan could impact small biotech companies, reducing their innovation by 90 percent, says new research.
A recent industry report projects a boom in the biosimilars market over the next three years and highlights key considerations for meeting its potential.
After regulatory approval, Bristol-Myers Squibb has announced its successful acquisition of Celgene, completing the merger.
The preference for orally disintegrating tablets (ODT) to treat CNS-related diseases will increase the market from $12bn in 2018, with a solid growth rate.